Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR in Rendu-Osler-Weber patients with gastrointestinal bleeding
2016-001340-19Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in hereditary hemorrhagic telangiectasia (HHT), gastrointestinal bleeding and refractory anemia (RA), sponsored by Radboud University Medical Center. Primary endpoint: Primary response to treatment. Started Jul 2016; status: completed.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)gastrointestinal bleedingrefractory anemia (RA)
Beyond the preview
Go deeper on 2016-001340-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001340-19.